Marinomed Biotech AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MARI.VI research report →
About the company
Marinomed Biotech AG is an Austrian-based biopharmaceutical firm dedicated to developing therapeutic solutions for viral and immunological conditions, with its market presence spanning across Austria, other European nations, and globally. Their comprehensive product pipeline includes Budesolv, which addresses allergic rhinitis and autoimmune gastritis, and Tacrosolv, currently undergoing Phase II clinical trials for anterior inflammatory eye diseases. Also featured in their development are Carravin, designed to alleviate nasal congestion, and Inhaleen, which is in Phase I clinical evaluation for viral pneumonia.
- CEO
- Andreas Grassauer
- IPO
- 2019
- Employees
- 31
- HQ
- Korneuburg, AT
Price Chart
- Market Cap
- $17.99M
- P/E
- 1.08
- P/S
- 2.34
- P/B
- -1.69
- EV/EBITDA
- 1.50
- Div Yield
- 0.00%
- Gross Margin
- 25.97%
- Op Margin
- 242.86%
- Net Margin
- 198.70%
- ROE
- -85.10%
- ROIC
- 293.20%
- Revenue
- $7.70M · 62.21%
- Net Income
- $15.30M · 199.24%
- EPS
- $8.32 · 195.96%
- Op Income
- $18.70M
- FCF YoY
- 0.00%
- 52W High
- $21.00
- 52W Low
- $8.60
- 50D MA
- $11.02
- 200D MA
- $16.70
- Beta
- -0.19
- Avg Volume
- 3.85K
Get TickerSpark's AI analysis on MARI.VI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MARI.VI coverage
Recent articles, reports, and earnings notes.
No research on MARI.VI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MARI.VI report →